- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Which are most effective topical treatments of Atopic dermatitis?
Canada: A systematic review and meta-analysis have shed light on the most effective topical treatments for atopic dermatitis (eczema). The findings were published online in The Journal of Allergy and Clinical Immunology on September 06, 2023.
The researchers reported tacrolimus, pimecrolimus, and moderate-potency topical corticosteroids (TCS) to be among the most effective in improving and maintaining multiple atopic dermatitis (AD) outcomes. They revealed topical antibiotics to be among the least effective.
High-certainty evidence revealed that pimecrolimus improved six out of seven patient-important outcomes -- including itch, AD severity, sleep disturbance, eczema-related quality of life, any adverse events, AD flare, discontinuation of treatment due to adverse events. Both high and low-dose tacrolimus improved five of seven.
With moderate- to high-certainty evidence, TCS in Groups 4 and 5, indicating moderate potency, improved four and six of these outcomes, respectively. Whether used alone or in combination with other treatments, topical antibiotics were shown to be one of the least effective options.
Atopic dermatitis is a common skin condition with multiple topical treatment options, but comparative effects are uncertain. Derek K. Chu, McMaster University, Hamilton, ON, Canada, and colleagues systematically synthesized the benefits and harms of AD prescription topical treatments.
For the 2023 AAAAI/ACAAI JTFPP AD guidelines, the researchers searched online databases for randomized trials addressing AD topical treatments. Paired reviewers independently screened records, extracted data and evaluated the risk of bias. Random-effects network meta-analyses addressed AD severity sleep, itch, AD quality of life, harms, and flares. Topical corticosteroids were classified using seven classes—group 1 being the most potent.
The authors reported the following findings:
· 219 included trials comprising 43,123 patients evaluated 68 interventions.
· With high certainty, pimecrolimus improved six of seven outcomes—among the best for two; high-dose tacrolimus (0.1%) improved five—among the best for two; low-dose tacrolimus (0.03%) improved five—among the best for one.
· With moderate-to-high certainty, group 5 TCS improved six—among the best for three; group 4 TCS and delgocitinib improved four—among the best for two; ruxolitinib improved four—among the best for one; group 1 TCS improved three—among the best for two. These interventions did not increase harm.
· Crisaborole and difamilast were intermediately effective, but uncertain harm.
· Topical antibiotics alone or in combination may be among the least effective.
· To maintain AD control, group 5 TCS were among the most effective, followed by tacrolimus and pimecrolimus.
The researchers' team noted that most of the studies were determined to be at low risk for bias, with missing outcome data providing the most frequent risk of bias. The included trials spanned over 50 years of data, but some smaller studies may have been missed.
The researchers wrote, "Despite these limitations, the study findings show that AD is driven by multiple different inflammatory pathways similar to other allergic diseases. There is a need for further research to better help patients choose an AD treatment,"
Reference:
Chu DK, Chu AWL, Rayner DG, Guyatt GH, Yepes-Nuñez JJ, GomezEscobar L, Pérez-Herrera LC, DÃaz Martinez JP, Brignardello-Petersen R, Sadeghirad B, Wong MM, Ceccacci R, Zhao IX, Basmaji J, MacDonald M, Chu X, Islam N, Gao Y, Izcovich A, Asiniwasis RN, Boguniewicz M, De Benedetto A, Capozza K, Chen L, Ellison K, Frazier WT, Greenhawt M, Huynh J, LeBovidge J, Lio PA, Martin SA, O’Brien M, Ong PY, Silverberg JI, Spergel JM, Smith Begolka W, Wang J, Wheeler KE, Gardner DD, Schneider L, Topical treatments for atopic dermatitis (eczema): systematic review and network meta-analysis of randomized trials, Journal of Allergy and Clinical Immunology (2023), doi: https://doi.org/10.1016/j.jaci.2023.08.030.
MSc. Biotechnology
Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at  editorial@medicaldialogues.in. Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751